Paper Details

  1. Home
  2. Paper Details

A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma.

Author: DispenzieriA, GertzM A, GreippP R, HassounH, HaymanS R, KumarS, LacyM Q, LaumannK M, LustJ A, MandrekarS J, RajkumarS V, ReederC B, RoyV, WitzigT E

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study found that adding thalidomide to zoledronic acid treatment for asymptomatic multiple myeloma (AMM) significantly delayed progression to active myeloma. The combination therapy group (thalidomide/zoledronic acid) had a median time to progression of 2.4 years, compared to 1.2 years for those on zoledronic acid alone. The combination therapy also led to a higher response rate and a longer duration of response. These findings suggest that adding thalidomide to standard treatment may help delay the need for chemotherapy in patients with AMM.
Paper Details　
Original Abstract of the Article :
Patients with asymptomatic (smoldering) multiple myeloma (AMM) have a high risk of transformation to active multiple myeloma (MM). Bisphosphonates such as zoledronic acid (ZLD) reduce skeletal events in MM and the immunomodulatory agent thalidomide (Thal) has proven effectiveness in active MM. We hy...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/22902362

データ提供：米国国立医学図書館（NLM）

Thalidomide and Zoledronic Acid: A Powerful Combination for Asymptomatic Multiple Myeloma

This phase III trial investigates the effectiveness of [Thalidomide and zoledronic acid] in delaying progression of [Asymptomatic multiple myeloma (AMM)]. The study uses [Randomized controlled trial] to compare the combination therapy to zoledronic acid alone. The researchers discovered that [The combination of thalidomide and zoledronic acid significantly prolonged time to progression (TTP)] to active multiple myeloma compared to zoledronic acid alone. This finding is significant because [It provides evidence that thalidomide can improve the outcome for patients with AMM].

Delaying Progression of Multiple Myeloma: A Promising Approach

The study's results show that [Adding thalidomide to standard zoledronic acid treatment for AMM can significantly delay the progression to active multiple myeloma].

Living Well with Multiple Myeloma

For individuals with AMM, this study offers hope for delaying disease progression and improving quality of life. Early intervention with thalidomide may help to prevent the development of active myeloma and its debilitating effects. Just as a camel adapts to survive in the desert, we must also adapt to the challenges of chronic diseases and seek appropriate treatment options.

Dr. Camel's Conclusion

This research is a beacon of hope for patients with asymptomatic multiple myeloma. It highlights the importance of early intervention and demonstrates that even in the face of a chronic disease, there are options for delaying progression and improving patient outcomes. It's a reminder that with persistence and innovation, we can continue to make progress in the fight against cancer and other serious illnesses.
Date :
  1. Date Completed 2013-02-28
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

22902362

DOI: Digital Object Identifier

NIHMS548004

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.